Benefits of bone marrow-derived mesenchymal stem cells primed with estradiol in alleviating collagen-induced arthritis.

Publisher: Mashhad University of Medical Sciences Country of Publication: Iran NLM ID: 101517966 Publication Model: Print Cited Medium: Print ISSN: 2008-3866 (Print) Linking ISSN: 20083866 NLM ISO Abbreviation: Iran J Basic Med Sci Subsets: PubMed not MEDLINE

Original Publication: Mashhad : Mashhad University of Medical Sciences

Objectives: To investigate the effects of the oestradiol (ES) pulsed bone marrow-derived mesenchymal stem cells (BM-MSC) to treat adjuvant-induced arthritis in Wistar rats.
Materials and Methods: BM-MSCs were pulsed with ES (0, 10,100, and 1000 nM) for 24 hr. RA was induced by collagen and Freund's Complete Adjuvant into the base of the tail of Wistar rats.
Results: The least effective concentration of ES that can promote potent anti-inflammatory properties in the MSC population is 100 nM. At this concentration, ES increases the inhibition of the polyclonal T lymphocyte proliferation, production of IDO, IL-10, Nitric oxide, and TGF-β, and expression of CXCR4 and CCR2 mRNA in the MSC population. Accordingly, the RA rats were treated with 2×106 MSCs or ES-pulsed MSCs (100 nM) on day 10 when all animals had developed signs of RA. ES-pulsed BM-MSCs reduced the severity of RA more profoundly than treatment with BM-MScs alone. The ability of ES-pulsed BM-MSCs to reduce symptoms and RA markers like CRP, RF, and nitric oxide was comparable to that of prednisolone. Prednisolone was more successful in reducing inflammatory cytokines than treatment with ES-pulsed BM-MSCs. ES-pulsed BM-MSCs were more successful in increasing anti-inflammatory cytokines than treatment with Prednisolone. The ability of ES-pulsed BM-MSCs to decrease the level of nitric oxide was comparable to that of prednisolone.
Conclusion: ES-pulsed BM-MSCs may be a helpful strategy in RA control.
Competing Interests: None.

Iran J Basic Med Sci. 2015 Jul;18(7):672-6. (PMID: 26351558)
Stem Cells Transl Med. 2019 Aug;8(8):746-757. (PMID: 30964245)
Int Immunopharmacol. 2020 Jul;84:106602. (PMID: 32417655)
Arch Razi Inst. 2021 Oct 31;76(4):903-912. (PMID: 35096326)
Cells Tissues Organs. 2001;169(1):12-20. (PMID: 11340257)
Rheumatol Int. 2012 Jun;32(6):1605-9. (PMID: 21331575)
Nat Protoc. 2007;2(5):1269-75. (PMID: 17546023)
Cytotherapy. 2015 Jan;17(1):46-57. (PMID: 25457279)
Front Immunol. 2021 Mar 29;12:649786. (PMID: 33859641)
RSC Adv. 2021 Feb 10;11(13):7129-7137. (PMID: 35423287)
Phytomedicine. 2007 Dec;14(12):806-14. (PMID: 17689939)
Inflammopharmacology. 2022 Jun;30(3):935-944. (PMID: 35428948)
Arthritis Res Ther. 2015 Feb 13;17:32. (PMID: 25888974)
Differentiation. 2016 Dec;92(5):291-297. (PMID: 27087652)
Nano Lett. 2019 Oct 9;19(10):6716-6724. (PMID: 31082252)
PLoS One. 2013 Jul 05;8(7):e67976. (PMID: 23861842)
Evid Based Complement Alternat Med. 2021 Jan 5;2021:8899143. (PMID: 33488761)
Free Radic Biol Med. 2007 Sep 1;43(5):645-57. (PMID: 17664129)
Med Sci (Basel). 2018 Apr 18;6(2):. (PMID: 29669993)
Life Sci. 2019 Dec 15;239:117037. (PMID: 31730863)
Cytometry B Clin Cytom. 2006 Nov 15;70(6):391-9. (PMID: 16977637)
J Mol Med (Berl). 2001 Jun;79(5-6):243-53. (PMID: 11485016)
J Mol Cell Cardiol. 2007 Jan;42(1):142-9. (PMID: 17070836)
Nitric Oxide. 2021 May 1;109-110:1-11. (PMID: 33571602)
Iran J Basic Med Sci. 2018 Sep;21(9):936-942. (PMID: 30524694)
Res Vet Sci. 2018 Jun;118:11-18. (PMID: 29334646)
Stem Cells Dev. 2012 Jan 20;21(2):228-38. (PMID: 21480782)
Inflammopharmacology. 2020 Dec;28(6):1457-1476. (PMID: 32948901)
Transplant Proc. 2007 Mar;39(2):573-6. (PMID: 17362785)
Life Sci. 2020 Apr 1;246:117420. (PMID: 32050085)
Iran J Allergy Asthma Immunol. 2018 Feb;17(1):68-77. (PMID: 29512371)
Rheumatol Immunol Res. 2021 Apr 13;2(1):19-25. (PMID: 36467904)

Keywords: Estradiol; Inflammation; Mesenchymal stem cells; Rheumatoid arthritis; Wistar rat

Date Created: 20230403 Latest Revision: 20230404

20240829

PMC10008397

10.22038/IJBMS.2023.68112.14882

37009006